Cargando…

More evidence intratumoral DHT synthesis drives castration-resistant prostate cancer

Detalles Bibliográficos
Autor principal:	Wilson, Elizabeth M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2014
Materias:	Invited Research Highlight
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3901888/ https://www.ncbi.nlm.nih.gov/pubmed/24369139 http://dx.doi.org/10.4103/1008-682X.122200

Ejemplares similares

Reappraisal of glucocorticoids in castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

What is the next generation therapeutic strategy for castration-resistant prostate cancer
por: Wen, Si-Meng, et al.
Publicado: (2015)

Enzalutamide in chemo-naïve castration-resistant prostate cancer: effective for most but not for all
por: Maughan, Benjamin L, et al.
Publicado: (2014)

Androgen receptor variant-7: an important predictive biomarker in castrate resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2015)

Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2019)

New therapies for relapsed castration-resistant prostate cancer based on peptide analogs of hypothalamic hormones
por: Schally, Andrew V, et al.
Publicado: (2015)

Further analysis of PREVAIL: enzalutamide use in chemotherapy-naïve men with metastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2014)

The metastatic castration-resistant prostate cancer treatment paradigm: more choices, more questions
por: Yu, Evan Y, et al.
Publicado: (2014)

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
por: Stein, Mark N, et al.
Publicado: (2014)

Prostate cancer metastasis-driving genes: hurdles and potential approaches in their identification
por: Chiang, Yan Ting, et al.
Publicado: (2014)

Enzalutamide: a new indication for nonmetastatic castration-resistant prostate cancer
por: Rhea, Logan P, et al.
Publicado: (2019)

Ailanthone: a new potential drug for castration-resistant prostate cancer
por: Peng, Shihong, et al.
Publicado: (2017)

Optimal treatment for castration-resistant prostate cancer
por: Izumi, Kouji, et al.
Publicado: (2014)

Extension of the therapeutic spectrum in castration-resistant prostate cancer: Osteoclast inhibition with denosumab
por: Wolff, Johannes M., et al.
Publicado: (2012)

Denosumab: Delay of bone metastasis in men with nonmetastatic castrate-resistant prostate cancer
por: Manger, Jules P., et al.
Publicado: (2012)

Radium-223 in metastatic castration resistant prostate cancer
por: Vuong, Winston, et al.
Publicado: (2014)

New developments in the treatment of castration resistant prostate cancer
por: Wadia, Roxanne, et al.
Publicado: (2014)

The role of glutamine metabolism in castration-resistant prostate cancer
por: Zhao, Bing, et al.
Publicado: (2023)

Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer
por: Markowski, Mark C, et al.
Publicado: (2015)

Transcriptional repression by androgen receptor: roles in castration-resistant prostate cancer
por: Gritsina, Galina, et al.
Publicado: (2019)

Current opinion and mechanistic interpretation of combination therapy for castration-resistant prostate cancer
por: Xu, Jin, et al.
Publicado: (2019)

Intratumoral steroidogenesis in castration-resistant prostate cancer: a target for therapy
por: Armandari, Inna, et al.
Publicado: (2014)

Prostate cancer screening: and yet it moves!
por: Kwiatkowski, Maciej, et al.
Publicado: (2015)

To screen or not to screen: the prostate cancer dilemma
por: Stone, Nelson N, et al.
Publicado: (2015)

The emerging role of prostate-specific membrane antigen (PSMA) PET-CT in patients with high-risk prostate cancer: moving the bar in high-risk prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2020)

External beam radiotherapy for localized prostate cancer
por: Yilmaz, Hasan, et al.
Publicado: (2015)

Testosterone replacement therapy and the risk of prostate cancer
por: Warburton, Daniel, et al.
Publicado: (2015)

Current and emerging trends in prostate cancer immunotherapy
por: Schatz, Adam, et al.
Publicado: (2019)

Androgen receptor functions in prostate cancer development and progression
por: Balk, Steven P
Publicado: (2014)

Prevention of erectile dysfunction after radiotherapy for prostate cancer
por: Faiena, Izak, et al.
Publicado: (2014)

Next generation patient-derived prostate cancer xenograft models
por: Lin, Dong, et al.
Publicado: (2014)

Long-term survival of participants in the prostate cancer prevention trial
por: Silberstein, Jonathan L, et al.
Publicado: (2014)

Management of localized prostate cancer: the pendulum swings (back to the middle)
por: Vuong, Winston, et al.
Publicado: (2014)

Lipogenic metabolism: a viable target for prostate cancer treatment?
por: Liang, Mengmeng, et al.
Publicado: (2014)

Transcriptome sequencing in prostate cancer identifies inter-tumor heterogeneity
por: Mendonca, Janet, et al.
Publicado: (2015)

HOXB13 and other high penetrant genes for prostate cancer
por: Pilie, Patrick G, et al.
Publicado: (2016)

Re: Long-term survival of participants in the Prostate Cancer Prevention Trial
por: Thompson, Ian M, et al.
Publicado: (2014)

Long noncoding RNA-mediated activation of androgen receptor in prostate cancer
por: Petrovics, Gyorgy, et al.
Publicado: (2014)

Tools to identify the men with prostate cancer most appropriate for active surveillance?
por: Getzenberg, Robert H
Publicado: (2014)

Use of early chemotherapy for hormone-sensitive prostate cancer: time for CHAARTED
por: Aragon-Ching, Jeanny B
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_p6k3je1gmpg31bl9sqet8729dp